sur CureVac (NASDAQ:CVAC)
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company focusing on mRNA-based medicines, announced the appointment of Dr. Mehdi Shahidi to its Supervisory Board. He replaces Ralf Clemens, who served from March 2016 to September 2023. Dr. Shahidi's expertise aligns with CureVac's focus on innovative technologies and mRNA-based cancer vaccines.
Dr. Shahidi, currently the CEO of Petalion Therapeutics and a Venture Partner at Medicxi, brings valuable experience in oncology and drug development. His prior roles include Senior Vice President at Boehringer Ingelheim, where he oversaw multiple drug approvals and clinical advancements.
His appointment begins in September 2024 at CureVac SE, with another appointment for CureVac N.V. to be considered at the next Annual General Meeting in June 2025. Dr. Shahidi looks forward to contributing to CureVac's pioneering work in mRNA technologies.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CureVac